-
1.发明申请公开(公告)号：US20080147178A1
公开(公告)日：2008-06-19
申请号：US11942693
申请日：2007-11-19
Applicant: Stephen Pacetti , Wouter Roorda
Inventor： Stephen Pacetti , Wouter Roorda
IPC: A61F2/82 , A61M25/10 , A61K47/32 , C08F218/02 , A61B17/00
CPC classification number: A61L27/54 , A61L27/34 , A61L29/085 , A61L29/16 , A61L31/10 , A61L31/16 , A61L2300/00 , C08L27/18
Abstract: Biocompatible copolymers are manufactured to include a zwitterionic monomer and an alkoxy acrylate monomer. The alkoxy acrylate monomer can be a 2-methoxyethyl methacrylate (MOEMA) or a 2-methoxyethyl methacrylate (EOEMA). Alternatively, the alkoxy acrylate can be 2-methoxyethyl acrylate (MOEA) or 2-ethoxyethyl acrylate (EOEA). The alkoxy acrylate monomers advantageously give the zwitterionic copolymers greater ductility, strength, and toughness while maintaining a desired amount of hydrophilicity. The improved toughness allows the zwitterionic copolymers to be processed without cross-linking, which improves the elongation properties of the zwitterionic copolymer, and reduces the risk of cracking during use.
Abstract translation: 制造生物相容性共聚物以包括两性离子单体和烷氧基丙烯酸酯单体。 烷氧基丙烯酸酯单体可以是甲基丙烯酸2-甲氧基乙酯（MOEMA）或甲基丙烯酸2-甲氧基乙酯（EOEMA）。 或者，烷氧基丙烯酸酯可以是丙烯酸2-甲氧基乙酯（MOEA）或丙烯酸2-乙氧基乙酯（EOEA）。 烷氧基丙烯酸酯单体有利地使两性离子共聚物具有更高的延展性，强度和韧性，同时保持所需量的亲水性。 改进的韧性使得两性离子共聚物在不交联的情况下进行加工，这提高了两性离子共聚物的伸长性能，并降低了使用过程中的开裂风险。
-
2.发明申请公开(公告)号：US20050142202A1
公开(公告)日：2005-06-30
申请号：US11015943
申请日：2004-12-17
Applicant: Wouter Roorda , Stephen Pacetti
Inventor： Wouter Roorda , Stephen Pacetti
IPC: A61K9/16 , A61K31/727 , A61K48/00 , A61K9/14 , A61K38/18
CPC classification number: A61K9/14 , A61K9/1617 , A61K9/1647 , A61K9/1658 , A61K9/1694 , A61K31/573 , A61K31/727 , A61K38/1825 , A61K47/26 , A61K47/36 , A61K48/00
Abstract: Compositions and methods of using the compositions to achieve a therapeutic effect are provided.
Abstract translation: 提供了使组合物达到治疗效果的组合物和方法。
-
公开(公告)号：US20060198897A1
公开(公告)日：2006-09-07
申请号：US11213288
申请日：2005-08-26
Applicant: Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
Inventor： Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
CPC classification number: A61K31/727 , A61K31/728 , A61K31/737 , A61L31/10 , C08L89/00
Abstract: Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed.
-
公开(公告)号：US20060018944A1
公开(公告)日：2006-01-26
申请号：US11213290
申请日：2005-08-26
Applicant: Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
Inventor： Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
IPC: A61K31/727 , A61F13/00
CPC classification number: A61K31/727 , A61K31/728 , A61K31/737 , A61L31/10 , C08L89/00
Abstract: Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed.
-
5.发明申请Morphology profiles for control of agent release rates from polymer matrices 审中-公开用于控制聚合物基质的试剂释放速率的形态概况公开(公告)号：US20080124372A1
公开(公告)日：2008-05-29
申请号：US11448956
申请日：2006-06-06
Applicant: Syed F. A. Hossainy , Fuh-Wei Tang , Lothar Kleiner , Thierry Glauser , Yiwen Tang , Wouter Roorda , Stephen Pacetti , Gina Zhang , Yung-Ming Chen , Andrew F. McNiven , Sean A. McNiven , Brandon J. Yoe
Inventor： Syed F. A. Hossainy , Fuh-Wei Tang , Lothar Kleiner , Thierry Glauser , Yiwen Tang , Wouter Roorda , Stephen Pacetti , Gina Zhang , Yung-Ming Chen , Andrew F. McNiven , Sean A. McNiven , Brandon J. Yoe
IPC: A61F2/06 , B05D3/00 , A61K47/48 , A61K31/436 , A61K31/337 , A61K31/46 , A61P9/00
CPC classification number: A61L31/10 , A61L27/40 , A61L27/44 , A61L27/50 , A61L27/54 , A61L31/12 , A61L31/14 , A61L31/16 , A61L2300/00
Abstract: The present disclosure teaches methods of controlling the release rate of agents from a polymeric matrix that include designing and creating a predetermined initial morphology (IM) profile in a polymeric matrix. The teachings indicate, inter alia, that control over the release rate of agents can provide for an improved control over the administration of agents as well as have an effect upon the mechanical integrity and absorption rate of the polymeric matrix.
Abstract translation: 本公开教导了控制来自聚合物基质的试剂的释放速率的方法，其包括在聚合物基质中设计和产生预定的初始形态（IM）分布。 教导尤其表明，对药剂释放速率的控制可以提供对药剂施用的改进控制，以及对聚合物基质的机械完整性和吸收速率的影响。
-
Patent Agency Ranking
公开(公告)号：US20050106203A1
公开(公告)日：2005-05-19
申请号：US10176504
申请日：2002-06-21
Applicant: Wouter Roorda , Ni Ding , Stephen Pacetti , Eugene Michal , Ashok Shah , Syed Hossainy
Inventor： Wouter Roorda , Ni Ding , Stephen Pacetti , Eugene Michal , Ashok Shah , Syed Hossainy
CPC classification number: A61L31/16 , A61L31/10 , A61L2300/416 , A61L2300/602 , A61L2300/606 , A61L2300/608 , A61L2420/08 , C08L33/10 , C08L33/06
Abstract: A coating for a medical device, particularly for a drug eluting stent, is described. The coating can include a polyacrylate, a blend of polyacrylates, or a blend of the polyacrylate with other polymers, for example, poly(ethylene-co-vinyl alcohol).
Abstract translation: 描述了用于医疗装置的涂层，特别是用于药物洗脱支架的涂层。 涂层可以包括聚丙烯酸酯，聚丙烯酸酯的共混物或聚丙烯酸酯与其它聚合物的共混物，例如聚（乙烯 - 共 - 乙烯醇）。
-
7.发明授权公开(公告)号：US07781551B2
公开(公告)日：2010-08-24
申请号：US11942693
申请日：2007-11-19
Applicant: Stephen Pacetti , Wouter Roorda
Inventor： Stephen Pacetti , Wouter Roorda
CPC classification number: A61L27/54 , A61L27/34 , A61L29/085 , A61L29/16 , A61L31/10 , A61L31/16 , A61L2300/00 , C08L27/18
Abstract: Biocompatible copolymers are manufactured to include a zwitterionic monomer and an alkoxy acrylate monomer. The alkoxy acrylate monomer can be a 2-methoxyethyl methacrylate (MOEMA) or 2-ethoxyethyl methacrylate (EOEMA). Alternatively, the alkoxy acrylate can be 2-methoxyethyl acrylate (MOEA) or 2-ethoxyethyl acrylate (EOEA). The alkoxy acrylate monomers advantageously give the zwitterionic copolymers greater ductility, strength, and toughness while maintaining a desired amount of hydrophilicity. The improved toughness allows the zwitterionic copolymers to be processed without cross-linking, which improves the elongation properties of the zwitterionic copolymer, and reduces the risk of cracking during use.
Abstract translation: 制造生物相容性共聚物以包括两性离子单体和烷氧基丙烯酸酯单体。 烷氧基丙烯酸酯单体可以是甲基丙烯酸2-甲氧基乙酯（MOEMA）或甲基丙烯酸2-乙氧基乙酯（EOEMA）。 或者，烷氧基丙烯酸酯可以是丙烯酸2-甲氧基乙酯（MOEA）或丙烯酸2-乙氧基乙酯（EOEA）。 烷氧基丙烯酸酯单体有利地使两性离子共聚物具有更高的延展性，强度和韧性，同时保持所需量的亲水性。 改进的韧性使得两性离子共聚物在不交联的情况下进行加工，这提高了两性离子共聚物的伸长性能，并降低了使用过程中的开裂风险。
-
公开(公告)号：US20070059434A1
公开(公告)日：2007-03-15
申请号：US11592632
申请日：2006-11-02
Applicant: Wouter Roorda , Syed Hossainy , Ni Ding , Fuh-Wei Tang , Stephen Pacetti
Inventor： Wouter Roorda , Syed Hossainy , Ni Ding , Fuh-Wei Tang , Stephen Pacetti
CPC classification number: A61L31/10 , A61L31/16 , A61L2300/416 , A61L2420/02 , A61L2420/08
Abstract: A method of coating an implantable medical device, such as a stent, is disclosed. The method includes applying a formulation on a first polymer layer containing a therapeutic substance to form a second layer. The formulation can contain a highly hydrophobic polymer or a solvent which is a poor solvent for the drug or the polymer of the first layer. The formulation can have a low surface tension value or a high Weber number value.
-
公开(公告)号：US20060002974A1
公开(公告)日：2006-01-05
申请号：US11212376
申请日：2005-08-26
Applicant: Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
Inventor： Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
IPC: A61K31/737 , A61K31/727 , A61K31/728 , A61F2/00
CPC classification number: A61K31/727 , A61K31/728 , A61K31/737 , A61L31/10 , C08L89/00
Abstract: Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed.
-
10.发明申请公开(公告)号：US20090286761A1
公开(公告)日：2009-11-19
申请号：US12191209
申请日：2008-08-13
Applicant: Jin Cheng , Stephen Dugan , Gordon Stewart , Gina Zhang , Nancy Kirsten , Paul Consigny , Christopher Feezor , Gene Park , Wouter Roorda , Syed F.A. Hossainy
Inventor： Jin Cheng , Stephen Dugan , Gordon Stewart , Gina Zhang , Nancy Kirsten , Paul Consigny , Christopher Feezor , Gene Park , Wouter Roorda , Syed F.A. Hossainy
CPC classification number: A61L31/16 , A61F2/91 , A61F2250/0067 , A61F2250/0068 , A61K31/4745 , A61K31/56 , A61K31/573 , A61L31/10 , A61L31/148 , A61L2300/222 , A61L2300/416 , A61L2300/45 , A61K2300/00
Abstract: A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).
Abstract translation: 提供了一种药物递送系统，其包括至少100杯依维莫司和氯倍他索，使得依维莫司与氯倍他索的比例至少为10：1（w / w），依维莫司的重量比为至少10倍 氯倍他索 该系统可以是支架。 还提供了治疗血管的再狭窄或易损斑块的方法，所述方法包括向患者局部施用选自雷帕霉素（西罗莫司），Biolimus A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司， 40-（2-羟基）乙基雷帕霉素（依维莫司），40-O-（3-羟基）丙基雷帕霉素，40-O- [2-（2-羟基）乙氧基]乙基雷帕霉素，40- O-四唑基雷帕霉素和40-表 - （N1-四唑基）雷帕霉素，并且对患者局部施用由氯倍他索组成的第二药物，其中局部施用的第一药物的最小量为100杯，其中 第二种药物的第一种药物例如为10：1〜100：1（w / w）。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.031 seconds)
